Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27174748 | 0.91 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL23069358 | 0.90 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL23069327 | 0.83 | TYMP (0.45) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL23069392 | 0.83 | KDM4E (0.42) | KDM4ETAS1R3TAS1R1HINT1TAAR1 | |
| SCHEMBL28515546 | 0.81 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1HINT1TAAR1 | |
| SCHEMBL23243908 | 0.81 | ADORA3 (0.46) | ALDH1A1ADORA3 | |
| SCHEMBL23069365 | 0.80 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL22301414 | 0.80 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL22704912 | 0.79 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1HINT1HPGD | |
| SCHEMBL26534322 | 0.79 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1HINT1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| CN-112105625-B | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 赛诺菲 | 2024-12-31 | — | — | CN | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116368146-A | Novel ligands for asialoglycoprotein receptors | 赛诺菲 | 2023-06-30 | — | — | CN | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2021-04-22 | — | — | US | disclosed |
| CN-112105625-A | Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same | 赛诺菲 | 2020-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | KDM4E 3880/4885TAS1R3 3463/4885TAS1R1 2885/4885 |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, RRM2B, RRM2 | KDM4E 3880/4885TAS1R3 3463/4885TAS1R1 2885/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | KDM4E 4376/4885TAS1R3 3302/4885TAS1R1 2475/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | KDM4E 3599/4885TAS1R3 3532/4885TAS1R1 3167/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | KDM4E 4002/4885TAS1R3 3924/4885TAS1R1 3586/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | KDM4E 3954/4885TAS1R3 2089/4885TAS1R1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.